Alfa Laval strengthens Flemingsberg – establishes itself in a growing city of the future

In May 2025, Alfa Laval moved into its new office and innovation center, spanning approximately 20,000 square meters, together with around 700 employees. At the same time, the restaurant K-märkt opened, further expanding the range of services available in Flemingsberg. The Royal Swedish Opera and Dramaten, Alfa Laval, Restaurant Billmans, and K-märkt all represent important pieces of the puzzle in the development of Flemingsberg.

It’s a warm May day when 700 Alfa Laval employees are welcomed to Flemingsberg with signs, balloons, and friendly faces guiding them to their new office. This will be their new workplace, located at the heart of one of Sweden’s largest urban development projects, with the ambitious goal of reaching 50,000 workers, 50,000 residents, and 50,000 visitors in Flemingsberg by 2050.

“We are very pleased to have established our new premises in Flemingsberg. This expansion represents a significant improvement for our employees, our operations, and our customers. Flemingsberg is now Alfa Laval’s hub for all development of separators within the marine, energy, food, and pharma sectors. We are also establishing our Innovation Centre for pharma here, further reinforcing our commitment to innovation and growth.”
– Peter Nielsen, Alfa Laval’s Site Manager for Flemingsberg and President of the Business Unit High Speed Separators

“We are very happy to welcome Alfa Laval to Flemingsberg and as a tenant of Fabege. Their presence strengthens the area’s position as a dynamic and innovative hub for research and development. We look forward to a continued successful collaboration that contributes to Flemingsberg’s ongoing growth and success.”
– Anna Nyberg, Head of Business Development at Fabege

Flemingsberg is not just a place you pass – it’s a place on the move.
Welcome to join us, too!

Published On: 3 December 2025
  • Now Open: Flemingsberg Science Award STARTUP 2026

    Do you have a business idea that can make a difference, locally or globally? Flemingsberg Science Award STARTUP is the competition for those who want to challenge their idea, gain valuable feedback from experienced experts, and take the first step toward building something real. 

  • Campus Flemingsberg continues to grow – more students and strong collaboration in focus

    Campus Flemingsberg remains one of Sweden’s most dynamic knowledge environments. Over the past year, the number of students has increased from 24,000 to approximately 27,000. The trend is clear: the campus’s broad academic profile continues to attract a growing number of students.

  • Limitless Potential: Winner of the Flemingsberg Science Award 2025

    Young people in disadvantaged areas often face mental health challenges and a lack of support, which can lead to isolation and destructive choices. Limitless Potential, winner of the Flemingsberg Science Award IDEA 2025, has created a safe space where creativity and social entrepreneurship come together to support youth.

  • Alfa Laval strengthens Flemingsberg – establishes itself in a growing city of the future

    In May 2025, Alfa Laval moved into its new office and innovation center, spanning approximately 20,000 square meters, together with around 700 employees. At the same time, the restaurant K-märkt opened, further expanding the range of services available in Flemingsberg. The Royal Swedish Opera and Dramaten, Alfa Laval, Restaurant Billmans, and K-märkt all represent important pieces of the puzzle in the development of Flemingsberg.

  • En nationell resurs för morgondagens behandlingar – nu är Karolinska ATMP Centrum invigt

    Med ett tydligt budskap om framtidstro och ett kraftfullt samarbete invigdes Karolinska ATMP Centrum i Flemingsberg i slutet av augusti. Centret är ett samarbete mellan Karolinska Institutet och Karolinska Universitetssjukhuset, och kommer fungera som en nationell resurs för tillverkning av avancerade terapier (ATMP), där forskning, kliniska prövningar och behandlingar smidigt samverkar för att leverera banbrytande terapier till patienter.